AbbVie’s ELAHERE demonstrates 32% reduction in death risk for ovarian cancer patients

Pallavi Madhiraju- March 15, 2025 0

A final analysis of the Phase 3 MIRASOL trial has confirmed that ELAHERE (mirvetuximab soravtansine-gynx) provides a significant survival advantage for patients with folate receptor ... Read More

GSK announces significant survival results for Jemperli in endometrial cancer trial

Pallavi Madhiraju- March 18, 2024 0

In a significant development for patients with primary advanced or recurrent endometrial cancer, GSK plc (LSE/NYSE: GSK) has disclosed promising outcomes for Jemperli (dostarlimab-gxly) from ... Read More